Lonza Group AG | Cash Flow

Fiscal year is January-December. All values CHF Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
87
237
277
301
728
Depreciation, Depletion & Amortization
309
299
300
307
411
Other Funds
3
2
29
65
22
Funds from Operations
505
667
679
839
1,053
Changes in Working Capital
25
174
68
85
176
Net Operating Cash Flow
530
493
747
754
877
Capital Expenditures
211
180
264
366
461
Sale of Fixed Assets & Businesses
20
8
6
2
2
Purchase/Sale of Investments
19
7
-
11
-
Net Investing Cash Flow
195
177
288
603
3,750
Cash Dividends Paid - Total
112
112
131
131
159
Issuance/Reduction of Debt, Net
336
313
279
133
346
Net Financing Cash Flow
451
421
381
151
3,165
Net Change in Cash
123
97
68
1
205
Free Cash Flow
336
335
491
399
450
Deferred Taxes & Investment Tax Credit
-
-
-
-
316
Net Assets from Acquisitions
4
-
30
230
3,310
Other Sources
19
2
-
2
20
Change in Capital Stock
-
2
-
48
2,956
Exchange Rate Effect
7
8
10
1
87
Other Uses
-
-
-
-
1

About Lonza Group

View Profile
Address
Muenchensteinerstrasse 38
Basel Basel-Stadt (Basle Town) 4002
Switzerland
Employees -
Website http://www.lonza.com
Updated 09/14/2018
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the Pharma&Biotech and Specialty Ingredients segemnts. The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as research and testing products and services.